C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.
about
Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in miceA Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma.Prognostic value of an immunohistochemical signature in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy.
P2860
C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@en
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@nl
type
label
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@en
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@nl
prefLabel
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@en
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@nl
P2093
P2860
P356
P1433
P1476
C-Met as a Molecular Marker fo ...... ciation with Clinical Outcome.
@en
P2093
Jin-Lin Hu
Jin-Ming Yu
Mao-Hui Yan
Wen-Yong Sun
Xiao-Jiang Sun
Ya-Ping Xu
P2860
P304
P356
10.7150/JCA.13687
P577
2016-03-18T00:00:00Z